Pharmaco - Today Stories

The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity  INDIANAPOLIS, Dec. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing facility that the company acquired earlier this year. This investment will extend the company's global parenteral (injectable) product manufacturing network, helping to meet the growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location. The company plans to start construction on the expansion next year. This represents another step in Lilly's hi…

The Hive is aimed at advancing research in life sciences by a novel approach to collaboration - creating an open innovation hub designed to build  close relationships between biotech companies, start-ups, academics, and Almirall scientists The network will be enlarged with the arrival of Admit Therapeutics and Microomics, in addition to the current members of the hub ZeClinics and Centrient Pharmaceuticals   This novel approach to pushing the boundaries of science and innovation in the year of Almirall’s 80th anniversary is part of the company’ s innovation strategy, long-term vision, commitment to patients, and the advancement of healthcare BARCELONA, Spain. December 4th, 2024 – Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “Th…

Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform Provides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 million GAITHERSBURG, Md., Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million. The agreement includes a transfer of assets, including a 150,000-square foot state-of-the-art recombinant protein manufac…

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has been lifted to 8th place in the 2024 Access to Medicine Index (ATMI), up from 13th in 2022. This improvement reflects the company’s strategic shift of prioritizing Health Equity as its primary contribution to the United Nations Sustainable Development Goals (UN SDGs).  Every two years the ATMI evaluates the efforts of the world's leading pharmaceutical companies and ranks the top 20 based on their efforts to improve access to medicine in low- and middle-income countries. Today, it has recognized Boehringer Ingelheim's substantial progress across key areas, particularly in Research & Development (R&D) and Product Delivery – due to a strong performance in capacity building and measuring outcomes.  "…

Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new role, Dr. Boshoff will remain a…

An Taoiseach, Simon Harris, TD, and Abbott Chairman and Chief Executive Officer, Robert Ford, attend official opening More than 800 to be employed at the diabetes technology manufacturing site, which is part of a €440 million investment Abbott is making across two sites in Ireland Facility will have the highest production of FreeStyle Libre® sensors in the world Abbott announces $100,000 grant to The Ireland Funds to support the education of young people from three DEIS schools located in Kilkenny ABBOTT PARK, Illinois – Nov. 18, 2024 – Abbott today marked the official opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland with a ceremony attended by An Taoiseach, Simon Harris, TD, and Abbott Chairman and Chief Executive Officer, Robert Ford. The site is a glob…

PORTAGE, Mich., USA – November 14, 2024 – Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio. Now integrated with Stryker’s Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals. Maternal mortality has been rising in the U.S. for decades,1 with approximately 50,000 cases of severe maternal morbidity occurring each year.2 Notably, 70% of pregnancy-related deaths due to hemorrhage are preventable.3 Stryker’s Triton software includes AI technology that can differentiate blood from…

Newly built 45,000 sq ft facility houses engineering and skilled manufacturing employees at Longbridge Business Park, a specialized hub for science and technology. Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth. New facility was constructed to BREEAM Very Good standard and achieved the highest Energy Performance Certificate rating. LONGBRIDGE, United Kingdom – November 13, 2024 – Waters Corporation (NYSE:WAT) announced the official opening of its new 45,000 square foot manufacturing facility at the Longbridge Business Park in the West Midlands. The new facility more than triples existing operations and enhances the company’s machining capacity to produce critical components for products developed and manufacture…

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumors With the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinations BioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 2025 BioNTech to pay $800 million to acquire 100 percent of the issued share capital and up to $150…

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1 DRD is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.2,3 There is an urgent need for earlier detection of DRD and novel treatments that work in earlier disease states before vision loss occurs.  Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term collaboration as Boehringer becomes the first pharmaceutical company to join the MTM Vision Consortium. Housed at the University of Michigan, the MTM Vision Consortium aims to unite innovators in the pre-competitive space from universities, f…

AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy. AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts A next generation manufacturing facility for biologics in Maryland Cell therapy manufacturing capacity on the West and East Coasts Specialty manufacturing in Texas Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the…

Professor Meritxell Huch, a director at the Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany receives this year’s Otto Bayer Award for her pioneering research on human organoids / Four early career scientists are honored with the Early Excellence in Science Awards for their boundary breaking research in the fields of Biology, Chemistry, Data Science and Medical Science. Leverkusen, November 6, 2024 – Professor Meritxell Huch receives this year’s Otto Bayer Award. The Otto Bayer Award is presented alternating with the Hansen Family Award every second year. The award recognizes leading scientists working in German-speaking countries for ground-breaking research in chemistry or biochemistry. The award with a prize money of EUR 75,000 was generou…

Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscience NORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ…

Prestigious award honors top pharmaceutical facility projects each year; showcases impressive engineering feats and technological innovation NORTH BETHESDA, Md., Oct. 14, 2024 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) has recognized Eli Lilly Kinsale Limited as the Overall Winner of the 2024 Facility of the Year Awards (FOYA) for its IE2b facility based in Kinsale, Ireland. The winner was announced and formally recognized during ISPE's FOYA Banquet and Awards Celebration held in conjunction with the 2024 ISPE Annual Meeting & Expo in Orlando, Florida. The vision for Eli Lilly's IE2b project was to marry innovative, advanced technologies into a first-of-its-kind hybrid manufacturing platform in order to optimize synthetic peptide production fo…

BERLIN – October 7, 2024 – EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced the continued growth of its European footprint with a new office in Berlin, Germany, Europe’s largest pharmaceutical market. The office opening represents the company’s continued investment in global commercial operations, including expanded critical infrastructure and commercial launch services across Europe. The location is the latest addition to EVERSANA’s real estate portfolio, including office locations in more than fifteen countries worldwide. The new facility is located in the Carre am Schnikelplatz building in the heart of Berlin and will serve as a destination for employee and client meetings throughout the region. “Over the years we have made smart…

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia. This asset further strengthens the company’s cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular disease.   Under the terms of the agreement, AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing this as a novel lipid-lowering therapy with potential in a range of cardiovascular disease indications alone or in combination, including with the oral small molecule PCSK9 inhibito…

Company Launches Accelerator™ Drug Development, 360° Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) Services that highlight advanced capabilities to help pharmaceutical and biotech customers solve global health challenges with new medicines and vaccines MILAN--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest innovations enabling the molecule-to-medicine journey and host a series of sessions that feature industry developments during CPHI Milan 2024, Oct. 8-10, in Milan, Italy. Leaders and experts from the company will be present at conference booth #7B18 to discuss how Thermo Fisher is supporting biotechnology and pharmaceutical companies across indications, modalities, sizes a…

The Almac Group has today announced an £11m investment and the creation of over 100 new jobs to expand its global analytical services capabilities. Over the past 18 months, Almac Sciences and Almac Pharma Services have jointly made this significant investment to expand their existing analytical laboratories, technology and resource to meet ongoing global demand. Almac employs over 700 highly skilled analysts working in regulatory approved GMP laboratories across five locations in Craigavon, UK; Charnwood, UK; Souderton, Pennsylvania; Athlone, Ireland and Dundalk, Ireland.  Construction of new laboratory space at the company’s global Headquarters in Craigavon considerably increases overall capacity, while additional upgrades and development of existing labs across all sites mean Almac will…

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, disability, and death caused by non-communicable diseases (NCDs). The start of the partnership was announced alongside the United Nations Global Assembly in New York. NCDs are a major global health issue. These diseases, which are not transmitted from person to person, cause 41 million deaths each year, accounting for 74% of all deaths worldwide.  With at least one in three people living with a NCD and half the world's population lacking essential health services, many are not receiving the care they need. Within the broad category of NCDs, there are specific types known as Card…

Provides patients with certain chronic lung conditions and retained secretions added comfort, user-friendly touch screen and unique garment design options Developed in consultation with clinicians and patients for an enhanced user experience The Vest uses High Frequency Chest Wall Oscillation therapy, a therapy for which Hillrom, now part of Baxter, has been a pioneer and industry leader BOSTON, Mass. - 2024-09-26 Baxter International Inc. (NYSE:BAX), a leading global medtech company, today unveiled its next generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference. The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system…